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Abstract
Background: Human African Trypanosomiasis (HAT) is caused by two trypanosome species,
Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Current drugs available for the
treatment of HAT have significant issues related to toxicity, administration regimes with limited
effectiveness across species and disease stages, thus there is a considerable need to find alternative
drugs. A well recognised approach to identify new drug candidates is high throughput screening
(HTS) of large compound library collections.
Results: We describe here the development of a luciferase based viability assay in 384-well plate
format suitable for HTS of T.b.brucei. The parameters that were explored to determine the final
HTS assay conditions are described in detail and include DMSO tolerability, Z', diluents and cell
inoculum density. Reference compound activities were determined for diminazene, staurosporine
and pentamidine and compared to previously published IC50 data obtained. The assay has a
comparable sensitivity to reference drugs and is more cost effective than the 96-well format
currently reported for T.b.brucei.
Conclusion:  Due to the reproducibility and sensitivity of this assay it is recommended for
potential HTS application. As it is commercially available this assay can also be utilised in many
laboratories for both large and small scale screening.
Background
Sleeping sickness, or Human African Tropanosomiasis
(HAT), is a disease caused by two species of trypano-
somes,  Trypanosoma brucei rhodesiense and  Trypanosoma
brucei gambiense. The disease occurs in 36 countries in sub
Saharan Africa. In 2006, there was an estimated cumula-
tive rate of 50000-70000 cases worldwide [1]. The disease
occurs in two stages, the first whereby trypanosomes mul-
tiply in the blood and lymphatic system, and includes
symptoms such as headaches, fever, joints pain and itch-
ing. In the second stage, trypanosomes cross the blood
brain barrier to the central nervous system and neurolog-
ical symptoms often become apparent. Without treatment
of the infection, the disease becomes fatal.
HAT chemotherapy relies upon a limited number of
drugs, which are not effective against all stages or trypano-
some species, have associated side effects or impractical
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administration regimes. Two of these drugs, suramin and
pentamidine, are only effective against the first stage of
disease, and are selective against T.b.rhodesiense  and
T.b.gambiense, respectively. Melarsoprol, which is effective
against the second stage of the disease, causes encepha-
lopathy in 5-10% of treated patients [2]. Eflornithine, also
a second stage specific drug, is less toxic however is not
effective against T.b.rhodesiense  [3]. Suramin, pentami-
dine, melarsoprol and eflornithine all require intravenous
injection for treatment which is not practical considering
the poor medical facilities in most of the disease endemic
areas. There also has been an increase in melarsoprol-
refractory sleeping sickness cases which suggests possible
emergence of melarsoprol-resistant trypanosomes [4,5].
The strong need for new, less toxic HAT drugs, which are
particularly effective against the second stage of the dis-
ease has resulted in a variety of approaches to identify new
treatments which are not uncommon approaches within
anti-parasitic drug discovery. These options include com-
binations of existing HAT drugs (such as eflornithine and
melarsoprol; [6]), new indications for existing drugs for
unrelated disorders and improvements to a number of
known drugs and compound classes [7]. High throughput
screening (HTS) of whole parasites against large com-
pound libraries has also been undertaken in the search for
new therapeutic candidates [8]. The application of HTS in
drug discovery has been explored in neglected disease area
for some time, as this approach has the potential of iden-
tifying new drugs with novel modes of action. Thus, HTS
remains an important consideration for HAT drug discov-
ery programmes.
HTS of specific targets have been reported in the literature
for T.brucei species. Assays in 384-well format have been
developed to detect trypanothione reductase activity
[9,10], however these do not involve the whole parasite.
There have been few reports in the literature for HTS
methods for whole cell screening for HAT. A viability
assay which has been extensively reported in the literature
for all T. brucei species and which utilises the dye Alamar
Blue™ has been used a 96-well format by a number of
authors [11-14]. We have recently developed a 384-well
Alamar Blue assay for T.b.brucei whole cell viability esti-
mation [15]. As an alternative to the Alamar Blue assay, a
luciferase viability assay has recently been published for
T.b.brucei whole cell screening in a 96-well format [16].
This paper reports the use of a bioluminescent ATP detec-
tion assay for HTS for a screening set of 2000 compounds.
The same author has also reported the use of this assay for
a smaller study of protease inhibitors against T.b.brucei
[17]. It would be of benefit, in terms of time and cost con-
siderations, to develop such a viability assay for T.b.brucei
whole cells in a 384-well format for HTS. T.b.brucei has
been routinely used in screening for initial identification
of anti-trypanosomal compounds for potential anti-HAT
drugs [7]. T.b.brucei causes trypanosomiasis in cattle [18]
and is non-infective to humans [19]. For identification of
lead compounds following HTS, actives are subsequently
screened against human infective HAT strains for confir-
mation of activity.
The luciferase based viability assay described here utilizes
firefly luciferase to detect intracellular ATP levels in viable
cells. The reaction involves the mono-oxygenation of luci-
ferin catalysed by luciferase in the presence of ATP, mag-
nesium and molecular oxygen, the reaction yielding a
luminescent signal. This assay has previously been used
for determining viability of various cell types, and numer-
ous kits are commercially available from a number of dif-
ferent suppliers. These kits, such as CellTiter- Glo®, are
quick and efficient, with only 10 minutes required for sig-
nal development. In comparison, the Alamar Blue assay
has a 6-24 hour incubation period for T.b.brucei cell via-
bility assays reported in a 96-well format [5,11-13].
Although many published 96 well assay formats employ
Alamar Blue development at 5% CO2 and 37°C inclusive
of a total assay incubation time, we recently found these
conditions to reduce the growth of T.b.brucei during 384
well plate assay optimisation [15]. We used a 24 hour
incubation at room temperature with Alamar Blue follow-
ing 72 hours of cell growth, for further signal develop-
ment, as cell growth was reduced under these conditions
(40 hours doubling time). We also found assay sensitivity
was not significantly affected by this extra incubation. In
this case, turn around would be faster for the luciferase
assay as the development of signal is more rapid.
Here we report the development of a 384-well whole cell
luciferase based viability assay for the detection of the via-
bility of T.b.brucei whole cells. This assay was developed to
HTS standards by incorporating the following statistical
parameters: Z' factor (Z'), % coefficient of variation (%
CV) and the signal to background assay window to reflect
reproducibility. The Z' is a measurement of the reproduc-
ibility of an assay as described by Zhang and others [20].
This value is an indicator of the quality of an assay by ana-
lysing the variation of samples of positive and negative
controls (no test compounds), and application of the use
of this parameter to define the reproducibility of assays
has been reported extensively [21]. An ideal assay would
have a Z' of 1. A Z' of 0 would define an assay that could
not be applied to screening due to poor reproducibility
[22] and therefore would require further optimisation.
The % CV denotes variation of an assay signal relative to
the mean. It can be applied to one control variable rather
than requiring both negative and positive controls. Gener-
ally, a Z' of greater than 0.5 with a % CV of less than 10 is
acceptable for HTS. A % CV of greater than 17% indicates
that the Z' will not reach 0.5 [23] and the closer to 0 theParasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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% CV is, the more reproducible, and therefore suitable an
assay will be for HTS.
Optimisation of the established assay into 384-well for-
mat incorporated analysis of assay variables such as cell
concentration, sensitivity to compound solvent, com-
pound dilution medium and the IC50 values of a panel of
reference compounds reported in the literature. The refer-
ence compounds used in this study consisted of the
known drugs, pentamidine, and diminazene and a gen-
eral kinase inhibitor, staurosporine. Diminazene and pen-
tamidine have reported IC50  values from various
publications which employ the Alamar Blue reagent for
viability detection [11-13]. Diminazene is a registered vet-
erinary drug used against T.b.brucei. Staurosporine has
reported activity against T.b.brucei [16], as well as other
trypanosome species, such as Trypanosoma cruzi [24] and
Leishmania species [25].
The luciferase based ATP detection assay described here
satisfies HTS assay criteria with a Z' of greater than 0.5. The
assay is comparable with respect to known reference com-
pound activities as those reported in the literature for the
Alamar Blue assay in format [11-13], as well as the
reported luciferase based assay in a 96-well format [16].
The parameters that were explored and optimised to pro-
vide a HTS assay in 384-well format are discussed in
detail.
Methods
Parasites and in vitro culture
T.b.brucei  bloodstream form strain 427 (BS427) was
kindly supplied by Dr Achim Schnaufer, (Institute of Cell
Biology, University of Edinburgh, UK) whilst at the Seattle
Biomedical Research Institute (Seattle, WA, USA). The
trypanosomes were maintained in log phase growth in 25
cm2 tissue culture flasks (vented, 25 cm2 Corning, Lowell,
MA, USA) by sub culturing at either 24 or 48 hour inter-
vals. Cells were grown in complete HMI-9 medium [26],
supplemented with 10% FCS and 100 IU/mL penicillin/
streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were
grown by incubating in conditions of 5% CO2 and 37°C
in a humidified atmosphere.
Statistical Analysis of Samples
For matrices of concentrations of cells and reagent, sam-
ple sets consisted of 8 wells. For initial set up experiments,
combinations of conditions were analysed by comparing
the signal to background ratio (cell concentrations versus
addition of the same volume of HMI-9 medium alone).
For larger well samples, over one third of a 384-well plate,
the signal to background ratio of control plates (1) and Z'
(3) were calculated as per Zhang and colleagues [20].
Whereby
(1) S/B = mean signal/mean background
(2) SD = standard deviation
(3) Z' factor = 1- [(3*SDA+3SDB)/(meanA-meanB)]
where A = mean end point signal of each assay (cell
growth detected in wells containing T.b.brucei in HMI-9
medium in a 384-well plate after 72 hours growth); B =
background signal, HMI-9 media incubated for 72 hours
with no cell addition, or with addition of 2.8 μM final
pentamidine concentration.
For all reference drug compound IC50 estimations, activity
at each compound dose was averaged from triplicate
experiments and expressed ± SD in nM.
Final optimised HTS assay conditions
The final optimised assay protocol, suitable for HTS, was
established through variation of the conditions used as
outlined. Unless stated otherwise, the basic HTS method
was used. All additions of reagents and cells were made
with a Multidrop™ liquid handler (Thermo Scientific,
Newington, NH) under sterile conditions. Fifty-five μL of
500 cells/mL of T.b.brucei in HMI-9 medium were added
to a white solid lidded 384-well plate (PerkinElmer,
Waltham, MA, USA). Cells were incubated for 24 hours at
37°C with 5% CO2 in humidified conditions before addi-
tion of 5 μL of compound prepared in 100% DMSO, or
100% DMSO only for control wells. Compounds and/or
DMSO were pre-diluted 1:40 in HMI-9 medium using a
MiniTrak™ robotic liquid handler (PerkinElmer,
Waltham, MA, USA). Five μL of diluted sample was added
to the each well using the MiniTrak, giving a final DMSO
concentration of 0.208%. Cells were incubated for a fur-
ther 48 hours at 37°C, resulting in a final incubation time
of 72 hours, of which trypanosomes were exposed to test
compounds for 48 hours. Fifteen μL of a luciferase based
reagent, CellTiter-Glo (Promega Inc, Madison, WI, USA)
was then added for detection of intracellular ATP. The
plate was shaken for 2 minutes to facilitate cell lysis and
the release of intracellular ATP, and then incubated for a
further 10 minutes at room temperature. The plate was
read on a TriLux plate reader (PerkinElmer, Waltham, MA,
USA), utilising a luminescence protocol.
Luciferase assay and detection of exogenous ATP
To establish the limits of detection for ATP, varying con-
centrations of ATP from 8 nM to 400 μM (in HMI-9
medium) were added to a 384-well plate (as outlined in
final assay conditions). Detection was performed by addi-
tion of 15 μL of the luciferase based reagent, as a mid-Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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range volume trialed for this assay (volumes of trypano-
somes were varied from 25 μL to 10 μL for initial growth
experiments). Fifty-five μL of each concentration of the
ATP solution were added to four 384-wells, with detection
as outlined in final assay conditions.
Doubling time of T.b.brucei in flask culture
The doubling time for T.b.brucei was originally calculated
to be 6.8 hours in a flask culture [15]. To determine if this
was constant over multiple T.b.brucei cell splits, the dou-
bling time was calculated at 24 hour intervals by main-
taining the final concentration of cells at 1 × 106cells/mL
and the cells were estimated to be in log phase over this
time period. The calculation was based upon manipula-
tion of the doubling time equation, using a known dou-
bling time of 6.8 hours.
To determine if the doubling time was stable at 6.8 hours,
the prepared culture dilution was signified as quantity
(q1) at time (t1) and the resultant density following 24
hours incubation was quantity (q2) at time (t2) as per the
doubling time equation:
Where Td = doubling time.
To compare the doubling time of a flask culture to that of
a culture in a well, the same cell density of trypanosomes
in 55 μL was added to wells of a white solid lidded 384-
well plate as to a flask culture, to gain an estimated 1 × 106
cells/mL following 24 hours growth. Three wells from the
plate and 3 replicates from the flask were counted and
compared for doubling time.
Detection of trypanosomes inoculated from flask grown 
cultures in to a 384-well plate
Fifty-five  μL of trypanosomes at 3 × 106cells/mL were
diluted to 1 and 2 × 106cells/mL, respectively and trans-
ferred directly to a 384-well plate. Twenty-five, 20, 15 and
10 μL of CellTiter-Glo reagent were added to the replicate
volumes of trypanosomes. Detection was as described in
the final assay conditions, with the only variation being
the reagent volume. The % CV and signal to background
ratio of well samples was used to define ideal reagent vol-
umes to employ for further assay set up for growth in 384-
well plates.
To further estimate the limitations of detection for the
ATP detection assay with respect to cell concentration, 55
μL of varying densities of trypanosomes in a larger range
of doses from 976 cells/mL to 3 × 106cells/mL in HMI-9
medium were added to a 384-well plate. Cultures diluted
from were at 3 × 106 cells/mL (for above 1 × 106 cells/mL
density); and 1 × 106 cells/mL. Detection was undertaken
as described in the final assay conditions.
Growth and detection of trypanosomes in 384-well plate
Plates were inoculated at a variety of cell concentrations
from 0 to 4000 trypanosomes/mL in 55 μL of HMI-9
medium and incubated at 37°C in 5% CO2 for 72 hours.
Three wells were harvested and counted with a haemocy-
tometer at each 24 hour period to estimate growth. Cell-
Titer-Glo reagent was added to each cell concentration at
each time interval at either 10 or 15 μL additions for com-
parison. The signal to background ratio and % CV of sam-
ple wells for each assay and trypanosome/reagent volume
combinations were estimated. To obtain statistically rele-
vant data each treatment was performed over 8 wells of
replicates.
Reference Compound IC50 determination
The IC50 value of each reference compound was calculated
by plotting % inhibition (100% inhibition was equal to
2.8 μM final pentamidine) against log [reference com-
pound] in the software package PRISM 4 graph pad
(denoted IC50 by PRISM). The IC50 value was the concen-
tration of compound that was estimated to lead to 50% of
growth; with the minimum of 0% growth (cells co-incu-
bated with 2.8 μM pentamidine) and 100% growth (no
compound addition). Each dose was screened in tripli-
cate.
Optimisation of DMSO concentration and compound 
dilution medium
Fifty-five μL of T.b.brucei at a density of 500 cells/mL was
inoculated into a 384-well plate and incubated for 24
hours. Five μL of varying concentrations of DMSO diluted
in HMI-9 medium with no FCS were added to each plate.
Plates were incubated for a further 48 hours and the HTS
protocol, as outlined in the final assay conditions, was
undertaken. One quarter of a 384-well plate was used to
calculate the Z' for each treatment.
The final assay conditions for the HTS protocol as out-
lined in the methods were used to estimate the IC50 values
of the reference compounds pentamidine, diminazene
and staurosporine in three independent experiments. The
final optimised conditions included an inoculum of 500
cells/mL, 15 μL of CellTiter-Glo and a final DMSO con-
centration of 0.208%, with no FCS in the dilution
medium.
For optimisation of compound dilution medium, addi-
tions of HMI-9 medium, water, HMI-9 medium without
FCS supplement and PBS were compared with respect to
assay sensitivity to reference compounds. The final assay
conditions used in this experiment were varied only by
the diluent used.
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Results
Luciferase assay signal from exogenous ATP
The luciferase assay could detect ATP concentrations with
a signal window (to background of HMI-9 medium with
no ATP addition) down to the lowest dose tested at a final
concentration of 8 nM, with a 15 μL addition of detection
reagent to 55 μL of ATP solution in HMI-9 medium. The
signal window was 24.5 ± 2.6 times that of media with no
ATP, with a mean signal of 90.4 ± 9.4 CPM for 8 nM of
ATP. The highest concentration that could be detected
within the linear range was 40 μM ATP with a signal win-
dow estimated to be 2.9 × 104 ± 1439 times with a lumi-
nescent signal of 9.1 × 104 ± 3504 CPM (Figure 1A). There
was a linear relationship to this point, with an r2 estimated
at 0.96 (Figure 1B). The signal had begun to plateau at 400
μM, with a mean value of 1.70 × 105 ± 5600 CPM (Figure
1A).
Doubling time of T.b.brucei in flask culture
The doubling time in a flask of T.b.brucei cultures of cells
did not vary from the estimate previously made at 6.8
hours. We did not find a significant variation in a flask
versus plate culture doubling time with a ratio of 0.97 ±
0.05 over 3 replicate independent experiments.
Detection of trypanosomes from a flask grown culture 
transferred directly to a 384-well plate
A decrease in the cell density of trypanosomes from 3 to 1
× 106 cells/mL, for all of the luciferase reagent volumes
tested, resulted in an increase in the mean CPM, with the
highest counts seen at 1 × 106cells/mL (Figure 2). Detec-
tion with 25 μL of luciferase reagent resulted in the great-
est signal window across treatments; with a maximum of
a 657 times window of cells to HMI-9 medium with no
cell addition, and a % CV of 8.8%. A reduction to 20 μL
reduced the % CV to 5.2% and to 15 μL the % CV was
3.7%. The signal window for 15 uL of reagent was 646
times. In consideration of cell growth likely resulting in
higher well to well variation compared with direct inocu-
lation in the plate, the lowest % CV with the highest signal
window at 1 × 106 cells/mL was used as a criteria for the
concentration and volume used for further investigation,
which was with addition of 15 μL of the CellTiter-Glo rea-
gent.
Figure 3A shows that the trend of a reduction in CPM seen
in initial experiments from densities of 1-3 × 106cells/mL
was replicated with a 15 μL detection volume of luciferase
and 55 μL of trypanosomes, with intermediate doses. Cell
concentrations were at 3 to 0.75 × 106 cells/mL then in
0.5× increments from 0.5 × 106 cells/mL to 488 cells/mL.
Detection of 3 × 106 cells/mL of trypanosomes resulted in
a mean CPM of 1.1 × 104 ± 1046, with a CV of 9.6%. A
reduction of the cell density to 1 × 106 cells/mL resulted in
an increased signal, with a reduced % CV, to 7.5%. Detec-
tion of 2 × 106 cells/mL resulted in a mean CPM of 1.2 ×
104 ± 911 and CV of 8.9%; however the signal had pla-
teaued from 1 × 106 cells/mL. The greatest signal window
closest to the linear end of detection was therefore
observed to be at a 1 × 106 cells/mL density (Figure 3B).
Growth and detection of trypanosomes in 384-well plate
Initial studies indicated that 1 × 106 cells/mL, with 15 μL
of detectant, provided an optimum signal to background
Detection of exogenous ATP with the luciferase assay Figure 1
Detection of exogenous ATP with the luciferase assay. (A) Fifty-five μL of ATP in HMI-9 medium detected by 15 μL of 
CellTiter-Glo reagent over a dose range resulting in a plateau of the signal at 400 μM. (B) Representation of a linear range of 
ATP detection with CellTiter-Glo over varying concentrations of ATP. Linearity was approximately 40 μM before the signal 
plateau. Each concentration was screened in triplicate. The experiment was repeated twice.Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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ratio for the assay. To determine the most suitable inocu-
lum density to obtain an optimal parasite growth in a
384-well plate, whilst taking into consideration assay per-
formance over a 72 hour period, the cell number used as
the inoculum per well was titrated as follows 0, 62, 125,
250, 500, 1000, 1500 and 2000 cells/mL. Growth by cell
count estimations of cells following 72 hours incubation
are shown in Figure 4. Approximately 3 × 106cells/mL was
the maximum attainable number using an inoculum of
2000 cells/mL. An increase in inoculum to 3000 cells/mL
resulted in a decrease in cell number. The signals obtained
for differing cell concentrations, with 10 and 15 μL of luci-
ferase reagent are shown in Figure 5. The greatest assay sig-
nal to background window was obtained when 15 μL of
the luciferase reagent was used for detection of trypano-
somes. With a 10 μL detection reagent addition across cell
concentrations a reduced signal was observed. The lowest
% CV and greatest window combination was observed
using an inoculum of 500 cells/mL. This inoculum pro-
duced 1.7 × 106 cells/mL (Figure 4). A slight decrease in
CPM was seen from 1000 cells/mL inoculum (a final den-
sity of 2.7 × 106 cells/mL) and a plateau of the signal from
2000 cells/mL inoculum (a final cell density of over 3 ×
106 cells/mL).
Combination of cell concentrations of T.b.brucei and reagent  volumes for signal detection when a 384-well plate inocu- lated directly from flask culture dilutions and detected by the  luciferase ATP detection assay Figure 2
Combination of cell concentrations of T.b.brucei and 
reagent volumes for signal detection when a 384-well 
plate inoculated directly from flask culture dilutions 
and detected by the luciferase ATP detection assay. 
Fifty-five μL of T.b.brucei cell densities ranging from 1-3 × 106 
cells/mL were transferred from a flask culture in to a 384 
well plate and detected with CellTiter-Glo. Twenty-five, 20, 
15 and 10 μL volumes of CellTiter-Glo were compared for 
signal detection and reproducibility.
T.b.brucei cells directly transferred from a flask culture to a 384 well plate and ATP detected with 15 μL luciferase based rea- gent Figure 3
T.b.brucei cells directly transferred from a flask culture to a 384 well plate and ATP detected with 15 μL luci-
ferase based reagent. (A) Cell concentrations of T.b.brucei and detection by the luciferase based assay of 55 μL per well of 
over a dose range to 3 × 106 cells/mL with cells transferred directly from dilutions made from flask grown cultures. 15 μL of 
luciferase reagent was added for detection. The mean CPM was estimated over 4 replicates from two separate experiments. 
(B) There was a linear relationship between cell number and trypanosomes to 1 × 106 cells/mL (r2 = 0.99).Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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Reference compound IC50 estimation and cell inoculum
Reference compounds (outlined in methods) were
screened over a dose range of cell inoculum densities of
2000, 1500, 1000, 500 and 250 cells/mL and estimations
of reference compound IC50 values were initially under-
taken by the serial dilution of compound stocks in 100%
DMSO in to HMI-9 medium (Table 1). A 5 μL volume of
these dilutions was added to each well, following an ini-
tial 24 hours incubation of cells in the absence of the com-
pound, which was to determine cell growth in the plate,
and to allow the equilibration of growth of the parasite in
the plate. The DMSO concentration used was at a final
concentration of 0.27% at the top dose in the assay for
diminazene, 0.08% for pentamidine and 0.20% for stau-
rosporine, DMSO is less likely to significantly affect the
assay at these low concentrations. The next serial dilution
was at a third of this concentration.
Reference IC50 values were compared to those previously
published from 96-well methodologies for the Alamar
Blue assay [11-13] and a 96-well methodology for the
luciferase assay [16]. A 500 cells/mL inoculum resulted in
an IC50 value of 123.4 nM for diminazene, 7.6 nM for
staurosporine (Table 1) and 3.6 nM for pentamidine
(results not shown). A reduction in the cell inoculum to
250 cells/mL reduced the IC50  value of compounds
slightly; diminazene 2 times and pentamidine 1.4 times,
however the staurosporine IC50 value was not affected.
Increasing the cell number resulted in a decrease in sensi-
tivity for all compounds, and an increase in the variability
of replicates.
Optimisation of DMSO concentration
Final DMSO concentrations from 0 to 8.3% DMSO were
initially tested for a 500 cells/mL inoculum and it was
found there was a decrease in the assay signal exhibited
from greater than 1% DMSO in the assay (Figure 6A). It
was found that using a final concentration of 0.5% DMSO
in the assay, however, resulted in a poor reproducibility
across the plate, with a Z' of 0.45 (results not shown).
Experiments were undertaken with a pre-dilution of
DMSO before addition to the plate, using a 1:20 and 1:40
dilution before the addition of 5 μL of this dilution vol-
ume to the assay volume (Figure 6B). The resulting final
DMSO concentrations were 0.417% and 0.208%, respec-
tively Results were replicated for both 250 and 500 cells/
Cell counts of T.b.brucei following growth at 72 hours in a  384-well plate Figure 4
Cell counts of T.b.brucei following growth at 72 hours 
in a 384-well plate. Varying inocula of trypanosomes were 
grown in 55 μL of HMI-9 media and harvested for counting 
after 72 hours growth.
Signal window and % CV of samples from varying inocula of trypanosomes following 72 hours growth and detection with the  luciferase viability assay Figure 5
Signal window and % CV of samples from varying inocula of trypanosomes following 72 hours growth and 
detection with the luciferase viability assay. The assay signal window and % CV after 72 hours growth with differing 
trypanosome inocula were compared with both 15 μL (A) and 10 μL (B) of detectant. The signal window was calculated from 
media without a cell addition.Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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mL inocula. The Z' for detection using a final DMSO con-
centration of 0.417% and a 500 cells/mL inoculum was
0.57. Decreasing the cell inoculum to 250 cells/mL
resulted in a Z' of -0.60%, reflecting poor reproducibility
for this cell concentration.
For a final DMSO concentration of 0.208%, the Z' was
increased to 0.65 (Figure 6B). For 250 cells/mL, a 0.208%
DMSO concentration gave a Z' of 0.15 which conse-
quently was not suitable for screening. The DMSO con-
centration may have to be diluted further to enable this
cell concentration to be employed in HTS.
Comparisons were made between manual and automated
additions of reagents for these dilutions. No difference in
the Z' was observed between the manual and automated
dispensing (results not shown).
Optimisation of compound dilution medium
Reference compounds diluted in water resulted in a
decrease in sensitivity when compared to results obtained
following dilution of compounds with HMI-9 medium
(Table 2). Dilutions made with HMI-9 medium without
FCS, compared with FCS containing medium, had a neg-
ligible effect on the estimated IC50 values excepting the
staurosporine IC50, increased slightly by 2.1 times. PBS
increased the IC50 values with the exception of dimina-
zene, by a factor of 1.8 and 2.1 times for pentamidine and
staurosporine respectively, in comparison to medium
with no FCS.
The mean IC50 values of reference compounds (n = 3)
were estimated using the final HTS conditions. Stau-
rosporine had an IC50 value of 1.94 ± 0.09 nM, dimina-
zene 60.88 ± 27.69 nM and pentamidine 11.91 ± 4.86
nM.
Discussion
A number of assay formats have been used to screen
trypanosome species including 3H-hypoxanthine incor-
poration, nuclear staining techniques, flow cytofluorome-
try and measurement of culture pH [27]. The Alamar Blue
assay was developed to improve associated assay variables
such as long incubations, costly reagents and poor assay
reproducibility/signal [14] and the assay has been exten-
sively reported in the literature [5,11-14]. More recently, a
luminescence assay to detect intracellular ATP has been
used in 96-well format [16,17]. Such an assay could be an
alternative assay for HTS to the commonly used Alamar
Blue assay. When comparing the feasibility of using these
assays one point is the necessity to add Alamar Blue under
sterile conditions, which may impact on potential robotic
manipulations. Some HTS robotic systems may not be
under sterile conditions and therefore the luciferase assay
may be favoured to decrease manual work associated with
Table 1: Luciferase assay estimated activities over varying 
T.b.brucei inocula for the reference compounds staurosporine 
and diminazene.
Cell density/mL Staurosporine Diminazene
2000 13.50 ± 8.5 453.8 ± 130.2
1500 19.90 ± 1.3 138.1 ± 4.4
1000 8.73 ± 3.2 178.2 ± 57.7
500 7.60 ± 0.6 123.4 ± 6.4
250 7.96 ± 1.2 61.80 ± 7.1
IC50values for each reference compound/cell inoculum concentration 
are expressed in ± standard deviation, in nM.
DMSO dose response curve for 500 cells/mL inoculum; and the Z' of pre-diluted DMSO at 0.417% and 0.208% final concentra- tion in the assay for a 500 and 250 cells/mL inoculum density Figure 6
DMSO dose response curve for 500 cells/mL inoculum; and the Z' of pre-diluted DMSO at 0.417% and 0.208% 
final concentration in the assay for a 500 and 250 cells/mL inoculum density. (A) DMSO standard curve from 0 to 
8.3% DMSO in the luciferase assay for a 500 cell/mL inoculum (B) DMSO concentration and Z' of 500 and 250 mL cell inocula 
with a pre-dilution of DMSO to decrease the assay concentration. The Z' was estimated from a quarter of a 384 well plate.Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
Page 9 of 12
(page number not for citation purposes)
the end point addition. However, the luciferase assay
requires plate shaking for cell lysis and not all HTS sys-
tems are capable of this step. Both assays are, however,
commercially available and this allows access to these rea-
gents for many laboratories for comparative develop-
ment, dependant upon the capability of the laboratory
equipment at hand.
We have described a luciferase based ATP detection assay
for estimation of T.b.brucei viability in a 384-well plate for
a detection of a small volume of trypanosomes (55 μL)
compared with previously employed 96-well protocols
which utilised a sample volume of 100 μL [16,17]. The
assay described here is reproducible, conforms to HTS
standards with a Z' of 0.65 (Figure 6B), and has similar
IC50 values for known T.b.brucei reference compounds as
previously reported Alamar Blue assays, a luminescent
viability assay (Table 3) and also to a recently reported
Alamar Blue assay in 384-well format [15].
Variables that were explored to determine the best condi-
tions to use in the 384-well assay included cell concentra-
tion, volume of detection agent, DMSO sensitivity and the
compound diluent. The concentration of the cell inocu-
lum to provide optimal cell growth and detection under
our experimental conditions was found to be 500 cells/
mL. For cell growth, an inoculum of 2000 cells/mL pro-
duced a maximum cell number of 3 × 106 cells/mL follow-
ing 72 hours incubation. In comparison, an inoculum of
3000 cells/mL resulted in a decrease in the final cell
number (Figure 4). This would be most likely attributed
to the fact that the culture is in decline, with the occur-
rence of observed cell death. We have previously seen this
decline in cultures exceeding over an approximated den-
sity of 3 × 106 cells/mL [15]. This density maximum den-
sity had also previously been determined from other
studies for other T.brucei bloodstream species to be 3 ×
106cells/mL [28]. The doubling time reported here was
calculated to be on average 6.8 hours which is also similar
to previously reported doubling times for other T. brucei
bloodstream species in HMI-9 medium [28].
A cell inoculum of 2000 cells/mL produced the maximum
cell number (Figure 4, just over 3 × 106 cells/mL) and this
cell concentration was synonymous with a slight decrease
in the luciferase signal in comparison to 1 or 2 × 106 cells/
mL with cells directly transferred from a flask (Figures 2
and 3). The signal was also reduced in comparison to cell
inocula of 1000 and 500 cells/mL grown in a plate (Figure
5). As cell number was at maximum from cells grown
from an inoculum of 2000 cells/mL, this signal decrease
could be a function of cells reaching a stationary phase of
growth and therefore the ATP production decreasing. This
phase related decline in ATP production has been
observed in other cell lines [29-31] and is synonymous
with a high cell density in fibroblast cell culture [32]. Cell
density has been shown to regulate trypanosome number
in infections by differentiation induced by stumpy induc-
tion factor at high concentrations [33], and it could be
suggested that other metabolites may be produced at
higher cell densities which effect cultures in monomor-
phic forms. As cells detected directly from a flask culture
exhibited a decrease in CPM at 3 × 106 cells/mL in com-
parison to 2 × 106 cells/mL (diluted from a 3 × 106 cells/
mL culture density; Figure 2), there may have also been
interference from ATPases released from the maximum
concentration of lysed cells, reducing the signal. This sig-
nal interference was not a function of the maximum ATP
that could be detected in the well, as this signal plateaued
at much higher CPM (Figure 1).
Titrating down to lower densities of trypanosomes
revealed a linear relationship between cell number and
signal between 1 × 103 to 1 × 106 cells/mL trypanosomes
from cells directly transferred from a flask grown culture
(Figure 3B). Mackey and colleagues [16] found a linear
relationship between trypanosome concentration and
Table 2: Reference compound IC50's from reference compounds diluted in water, HMI-9 medium with and without FCS and PBS.
Compound PBS Water FCS No FCS
Pentamidine 13.42 ± 7.5 57.78 ± 40 9.23 ± 0.71 7.56 ± 2.8
Diminazine 65.98 ± 1.7 140.6 ± 79 65.79 ± 21 62.46 ± 21.3
Staurosporine 10.99 ± 1.3 12.27 ± 3.0 2.43 ± 0.59 5.22 ± 1.1
IC50 values of compounds in variations of compound dilution media were determined in the luciferase assay and calculated from duplicate samples, 
expressed as ± SD, in nM.
Table 3: Reported activities for T.b.brucei reference compounds.
Compound Reference IC50 (nM) Assay
Diminazene [11] 90 Alamar Blue
Diminazene [12] 500 Alamar Blue
Diminazene [13] 990 Alamar Blue
Pentamidine [11] 10 Alamar Blue
Pentamidine [13] 40 Alamar Blue
Staurosporine [16] 7 Luciferase
IC50 values from various publications are listed for comparison. Assay 
formats include variations of the Alamar Blue viability assay and ATP 
detection using bioluminescence.Parasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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luciferase signal to 6 × 104 cells/well. As the inoculum for
this assay was 1 × 105 cells/mL, with a doubling time esti-
mated at 6.8 hours for example, the final assay concentra-
tion of cells following 48 hours incubation would have
reached over maximum, at 3 × 106 cells/mL, or 3 × 105
cells/well, so it can not be determined if a similar effect
was seen in this assay with the concentrations examined
for a linear trend.
With plate inoculated cultures, the cell number that pro-
duced the greatest signal window was 500 cells/mL (Fig-
ure 5). This inoculum resulted in approximately 1.7 × 106
cells/mL following 72 hours growth in plate (Figure 4).
This suggested a slightly faster doubling time in the plate,
as forecast by the doubling time equation this cell inocu-
lum should be under 1 × 106 cells/mL. However, at this
low cell inoculum, there is not a linear trend in growth as
we have previously observed [15], and therefore the dou-
bling time would not be expected to be constant. Relating
this concentration to the linearity of cell number versus
CPM from direct cell transfer, suggested that this cell con-
centration was slightly above the linear range of the assay,
which was at a maximum of 1 × 106 cells/mL (Figure 3B).
Taking this into consideration, it was determined that
reduction of the cell number to less than 1 × 106 cells/mL
final in the assay, or an inoculum of 250 cells/mL of
trypanosomes, could be applied for HTS. The DMSO tol-
erability for 250 compared with 500 cells/mL was
explored at both a 0.417% and 0.208% final DMSO con-
centration. The assay incorporating a 500 cells/mL inocu-
lum at 0.208% DMSO resulted in the least variability,
reflected in a Z' of 0.64 (Figure 6B). However, a 250 cells/
mL inoculum resulted in a Z' of less than 0.5 for both
DMSO concentrations and therefore was not acceptable
for HTS application. The DMSO concentration would
need to be further reduced to allow this inoculum to be
applied, which would bring about potential library con-
cerns as samples would have to be diluted further before
screening, therefore potentially reducing the sensitivity of
the assay at this cell density. Mackey and colleagues [16]
employed a DMSO concentration of 1% at the stage of cell
addition in a 96-well luciferase assay. The 384-well assay
would have an estimated cell number at the time of addi-
tion of DMSO of around 345 cells/well (estimating a dou-
bling time of 6.8 hours) in comparison to an estimated 1
× 104 cells/well in the 96-well format which could explain
the differences in the necessity for a lower DMSO require-
ment for 384-well screening using the HTS conditions as
outlined here.
Table 3 shows reference compound activities for both
reported Alamar Blue assays and a reported luciferase
based ATP detection assay in 96-well format. We found
that a 500 cell/mL inoculum resulted in IC50 concentra-
tions that were comparable to those found in the litera-
ture from dosing compounds with differing trypanosome
inocula. From Table 1, increasing the cell density
decreased the sensitivity to both diminazene and stau-
rosporine, when making comparisons of inoculums of
500 cells/mL with 2000 cells/mL. There was a 3.7 and 1.8
times reduction in the IC50values of diminazene and stau-
rosporine, respectively. A 3.3 times reduction in activity
was also revealed for pentamidine (results not shown). It
is not possible to directly compare the Alamar Blue assay
formats to the assay reported here due to the detection
reagents used, incubation time, media differences and cell
inoculation variables between assays. However, a similar
sensitivity was observed with results obtained by Lanteri
and collegues [11], with an IC50 value for pentamidine of
10 nM and diminazene 90 nM reported, compared to
those observed, pentamidine 11.91 nM and diminazene
60.88 nM. The sensitivity to staurosporine observed using
a 500 cells/mL inoculum (an IC50 of 1.94 nM) was com-
parable to the 96-well format previously reported [16]
(IC50 of 7 nM). As there may have been some interference
with a higher cell density used by these authors in com-
parison to the protocol reported here, and as stau-
rosporine has a high Hill Slope (> 3 over all cell doses),
further experiments would further determine sensitivities
between these assay formats with other known anti-
trypanosomals.
Importantly, the assay inoculum employed in the HTS
assay developed fits HTS statistical criteria The assay is
within the linear range of the detection of the reader (Fig-
ure 1), and approximately 0.7 × 106 cells/mL from the lin-
ear range of detection of cells estimated in the assay
system (Figure 3B). The assay at the defined cell inoculum
of 500 cells/mL has sensitivity to known compounds sim-
ilar to published reference compound activity in other
assay formats (Table 3).
The potential diluent used for the addition of compounds
and/or controls to the assay was explored, as pre-dilution
of DMSO, due to DMSO sensitivity, was necessary. During
a HTS campaign it is not uncommon for the screening
library to be pre-diluted into the assay plate prior to HTS
commencing. Exclusion of FCS from such a dilution
medium was considered as this may reduce the risk of cer-
tain contaminating microorganisms [34], considering
that there is a brief exposure of plates to the atmosphere
whilst the dilution is carried out. FCS has also been found
to influence cellular toxicity due to components binding
to inhibitor compounds [35] and therefore dilutions and
storage in a medium with FCS may potentially influence
compound activity. Thus, FCS was not included in the
diluents used here. The use of water as a diluent increased
the IC50 value of the reference compounds by 7.6, 2.3 and
2.4 times, respectively for pentamidine, diminazene and
staurosporine in comparison to medium without FCSParasites & Vectors 2009, 2:54 http://www.parasitesandvectors.com/content/2/1/54
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(Table 2). There was also a decrease in the cell number by
1.5 times with the water addition (results not shown).
This could have been as a result of a slight difference in the
buffering capacity of the system or an osmotic effect of
water on the cells, potentially causing cell lysis. For the
optimal 384-well assay performance, HMI-9 medium
with exclusion of the FCS component was the diluent of
choice, as it did not significantly change the IC50 value of
the reference compounds.
Conclusion
We have reported here the successful development and
optimisation of a luciferase based cell viability assay in
384-well format for use in HTS of T.b.brucei BS427, which
exhibits benefits compared with previously published
assay methodologies. Notably the assay is reproducible,
fits statistical parameters, with a similar sensitivity to
known drugs in comparison with previously published
results and is cheaper than the currently used 96-well
assay format for HTS. The assay described here is approx-
imately three times less expensive per well than the 96-
well luciferase assay currently reported in the literature.
Importantly, the assay is biologically relevant, and has
been shown statistically to perform well, adhering to the
Z' criteria imposed (cut off of 0.5, but closest to 1 as pos-
sible). Additions of assay reagents and cells were made
with automated liquid handlers, allowing for rapid addi-
tions for HTS and handling of a large plate numbers.
To our knowledge this is the first report of a 384-well cell
viability assay for T.b.brucei utilising cellular ATP estima-
tion, with a luciferase based detection agent. A future con-
siderations is the comparison of the luciferase based 384-
well assay to the Alamar Blue based 384 well assay [15] for
HTS application with a larger panel of compounds.
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